1. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline;Singh;J Clin Oncol,2022
2. Patterns of Response and Progression to Immunotherapy;Borcoman;Am Soc Clin Oncol Educ Book,2018
3. Gandara D , Reck M , Moro-Sibilot D , et al . Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer 2021;9:e001882. doi:10.1136/jitc-2020-001882
4. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
5. Zhou JG TJ , Wang H , Wong AHH , et al . Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with Immunotherapy. BMJ Oncology doi:0.1136/bmjonc-2023-000128